We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.5B
AUM Growth
+$439M
Cap. Flow
-$3.35M
Cap. Flow %
-0.06%
Top 10 Hldgs %
41.65%
Holding
136
New
22
Increased
21
Reduced
31
Closed
18

Top Buys

Rank Stock Value
1
MBX
MBX Biosciences
MBX
+$87.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$46.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$42.6M
4
AMGN icon
Amgen
AMGN
+$38.4M
5
UNH icon
UnitedHealth
UNH
+$37.9M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$74.9M
2
THC icon
Tenet Healthcare
THC
+$59.2M
3
VRNA
Verona Pharma
VRNA
+$41.4M
4
GERN icon
Geron
GERN
+$40.6M
5
PCVX icon
Vaxcyte
PCVX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
2 Miscellaneous 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDT
101
Ardent Health
ARDT
$1.51B
$3.79M 0.07%
+206,000
New +$3.64M
TRAW icon
102
Traws Pharma
TRAW
$7.96M
$3.56M 0.06%
605,531
+563,721
+1,348% +$5.13M
SIBN icon
103
CALL
SI-BONE Inc
SIBN
$845M
$3.5M 0.06%
250,000
– –
MIST icon
104
Milestone Pharmaceuticals
MIST
$113M
$3.04M 0.06%
2,000,000
– –
FLNA
105
PUT
Filana Therapeutics
FLNA
$33M
$2.8M 0.05%
+95,000
New +$2.19M
CMMB
106
Chemomab Therapeutics
CMMB
$17.9M
$2.73M 0.05%
435,318
-125,000
-22% -$701K
TIL icon
107
Instil Bio
TIL
$49.2M
$2.27M 0.04%
+33,700
New +$793K
HLSQ
108
Tessera Defense and Homeland Security Inc.
HLSQ
$2.65M
$1.82M 0.03%
9,409
+2,160
+30% +$783K
GERN icon
109
CALL
Geron
GERN
$842M
$1.82M 0.03%
400,000
-200,000
-33% -$909K
IVVD icon
110
Invivyd
IVVD
$246M
$1.76M 0.03%
1,728,300
-697,500
-29% -$756K
TSBX
111
DELISTED
Turnstone Biologics
TSBX
$1.73M 0.03%
3,099,265
– –
NXTC icon
112
NextCure
NXTC
$28.6M
$1.56M 0.03%
95,100
– –
VIGL
113
DELISTED
Vigil Neuroscience
VIGL
$1.53M 0.03%
448,891
– –
KZR
114
DELISTED
Kezar Life Sciences
KZR
$1.49M 0.03%
192,700
– –
CCCC icon
115
CALL
C4 Therapeutics
CCCC
$418M
$855K 0.02%
+150,000
New +$903K
ELEV
116
DELISTED
Elevation Oncology
ELEV
$565K 0.01%
941,275
– –
XERS icon
117
Xeris Biopharma Holdings
XERS
$1.36B
$229K ﹤0.01%
80,420
– –
ALXO icon
118
ALX Oncology
ALXO
$261M
– –
-1,894,462
Closed -$11.4M
APLM icon
119
Apollomics
APLM
$70M
– –
-85,655
Closed -$1.81M
BMRN icon
120
BioMarin Pharmaceuticals
BMRN
$12.4B
– –
-26,100
Closed -$2.15M
CATX icon
121
Perspective Therapeutics
CATX
$310M
– –
-492,670
Closed -$4.91M
DVAX
122
DELISTED
Dynavax Technologies
DVAX
– –
-113,500
Closed -$1.27M
DXCM icon
123
DexCom
DXCM
$32.8B
– –
-289,900
Closed -$32.9M
GERN icon
124
Geron
GERN
$842M
– –
-8,930,252
Closed -$40.6M
HRTX icon
125
Heron Therapeutics
HRTX
$59.6M
– –
-6,512,866
Closed -$22.8M
2 3 4
5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2024 Portfolio in Review

As of Q3 2024, OrbiMed held 136 positions worth $5.5B, up 8.7% from $5.06B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q3 2024 filing shows 22 new, 21 increased, 31 reduced and 18 closed positions. Its largest new stake was MBX Biosciences: 3,812,215 shares worth $99M. The largest sale was Janux Therapeutics, an estimated $74.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q3 2024 buy was MBX Biosciences: 3,812,215 shares worth $99M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2024, an estimated $42.6M increase.
  • OrbiMed's biggest Q3 2024 reduction was Janux Therapeutics, cutting an estimated $74.9M.
  • OrbiMed fully exited Verona Pharma in Q3 2024, selling an estimated $41.4M.
  • OrbiMed's ten largest holdings make up 42% of its $5.5B portfolio in Q3 2024.
  • OrbiMed opened 22 new positions and closed 18 in Q3 2024.
  • OrbiMed's portfolio value rose 8.7% quarter-over-quarter to $5.5B.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.